ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2015
Five-year biomarker progression variability for Alzheimer's disease dementia prediction: Can a complex instrumental activities of daily living marker fill in the gaps?
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI) as a Pre-Clinical or Pro-Dromal Alzheimers Diagnosis (Prognosis) for Optimum Outcomes
DNS Cohort Study Aimed at Understanding the Pathophysiology of AD and AD Related Disorders (ADRD)
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Prognostic and Predictive Factors in Early Alzheimer's Disease: A Systematic Review.Journal of Alzheimer's disease reports · 2024Pooled it
- Article
- Unwinding the Neurovascular Unit: The Vascular Extracellular Matrix and Mechanochemical Collagen Functionalization in Vascular Dementia.International journal of molecular sciences · 2026Review
- Overcoming the diagnostic gap in mild cognitive impairment in Parkinson's disease: a pilot study employing a machine learning-/augmented reality-based digital biomarker.Frontiers in aging neuroscience · 2026Article
- Longitudinal online weekly reports of non-cognitive symptoms and events can differentiate incident mild cognitive impairment from stable cognitively healthy older adults.Journal of Alzheimer's disease : JAD · 2025Article
- Early identification of cognitive impairment in older adults from Advanced Activities of Daily Living (AADL): A scoping review.Public health · 2025Article
- RADAR-AD: assessment of multiple remote monitoring technologies for early detection of Alzheimer's disease.Alzheimer's research & therapy · 2025Article
- Examining the Cognitive Underpinnings of Functional Decline in Prodromal Alzheimer's Disease: Insights From the Details of Functions of Everyday Life (DoFEL) Scale.Journal of aging research · 2025Article
- Digital Health Technologies for Alzheimer's Disease and Related Dementias: Initial Results from a Landscape Analysis and Community Collaborative Effort.The journal of prevention of Alzheimer's disease · 2024Review
- Augmented reality versus standard tests to assess cognition and function in early Alzheimer's disease.NPJ digital medicine · 2023Article
- Developing Early Markers of Cognitive Decline and Dementia Derived From Survey Response Behaviors: Protocol for Analyses of Preexisting Large-scale Longitudinal Data.JMIR research protocols · 2023Article
- Visual-spatial processing impairment in the occipital-frontal connectivity network at early stages of Alzheimer's disease.Frontiers in aging neuroscience · 2023Article
- Eliciting brain waves of people with cognitive impairment during meditation exercises using portable electroencephalography in a smart-home environment: a pilot study.Frontiers in aging neuroscience · 2023Article
- Description of the Method for Evaluating Digital Endpoints in Alzheimer Disease Study: Protocol for an Exploratory, Cross-sectional Study.JMIR research protocols · 2022Article
- Understanding 'passivity' in digital health through imaginaries and experiences of coronavirus disease 2019 contact tracing apps.Big data & society · 2022Article
- The Clinical Course of Early and Late Mild Cognitive Impairment.Frontiers in neurology · 2022Article
- Remote monitoring technologies in Alzheimer's disease: design of the RADAR-AD study.Alzheimer's research & therapy · 2021Article
- Subtle mistakes in self-report surveys predict future transition to dementia.Alzheimer's & dementia (Amsterdam, Netherlands) · 2021Article
- Utility of MemTrax and Machine Learning Modeling in Classification of Mild Cognitive Impairment.Journal of Alzheimer's disease : JAD · 2020Article
- Digital biomarker-based individualized prognosis for people at risk of dementia.Alzheimer's & dementia (Amsterdam, Netherlands) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBiomarker progressions explain higher variability in cognitive decline than baseline values alone. This study examines progressions of established biomarkers along with a novel marker in a longitudinal cognitive decline.
methodsA total of 215 subjects were used with a diagnosis of normal, mild cognitive impairment (MCI) or Alzheimer's disease (AD) at baseline. We calculated standardized biomarker progression rates and used them as predictors of outcome within 5 years.
resultsEarly cognitive declines were more strongly explained by fluorodeoxyglucose-positron emission tomography, precuneus and medial temporal cortical thickness, and the complex instrumental activities of daily living (iADL) marker progressions. Using Cox proportional hazards model, we found that these progressions were a significant risk factor for conversion from both MCI to AD (adjusted hazard ratio 1.45; 95% confidence interval 1.20-1.93; P = 1.23 × 10(-5)) and cognitively normal to MCI (adjusted hazard ratio 1.76; 95% confidence interval 1.32-2.34; P = 1.55 × 10(-5)). DISCUSSION: Compared with standard biological biomarkers, complex functional iADL markers could also provide predictive information for cognitive decline during the presymptomatic stage. This has important implications for clinical trials focusing on prevention in asymptomatic individuals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.